top of page

SITC 2024: Aulos Bioscience CEO Aron Knickerbocker describes the phase 1 and preliminary phase 2 data for the company's IL-2 redirecting antibody

He describes the safety and preliminary efficacy they have seen, including how patients are experiencing a lowering of Tregs. Plus, the future of the therapy in melanoma, lung cancer, and beyond.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

KH_Logo_Horizontal_Tagline_Black-1.png

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

bottom of page